Seagen Inc.

BioNTech’s acquisition of fellow German mRNA company CureVac underscored a trend in biotech: many companies form around new technologies, but not all succeed. A Very German Transaction BioNTech’s acq

Following up on last year’s approval of Vyloy (zolbetuximab) and looking to build its pipeline of antibody-drug conjugate (ADC) therapies for cancer, Astellas unveiled a licensing agreement with China

Taiho Pharmaceuticals said on 17 March that it will spend $400m up front and up to $740m in milestone payments to expand its cancer drug development pipeline through the acquisition of antibody-drug c

Developing antibody therapeutics, out-licensing the drugs to larger companies and collecting royalty revenue from the resulting commercial products has been a lucrative business for Genmab. However, f